Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

3.18
0.0000
Volume:- -
Turnover:- -
Market Cap:816.66M
PE:-94.97
High:3.18
Open:3.18
Low:3.18
Close:3.18
52wk High:4.18
52wk Low:1.10
Shares:256.81M
Float Shares:241.66M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0335
EPS(LYR):-0.1091
ROE:97.76%
ROA:12.04%
PB:-2.65
PE(LYR):-29.14

Loading ...

Archimed Completes Take-private of Esperion in Deal Valued up to $1.1 Billion

Reuters
·
Jul 13

Esperion Enters CVR Agreement Tied to Merger, Offering up to USD 100 Million Milestone Payout

Reuters
·
Jul 13

NASDAQ Trade Halt Continues Trading Halted; for Information Requested by NASDAQ at 03:28 Am

Reuters
·
Jul 12

NASDAQ Trade Halt Trading Halted; for Information Requested by NASDAQ at 07:50 Pm

Reuters
·
Jul 11

Esperion Stockholders Approve Merger Agreement at Special Meeting

Reuters
·
Jul 08

Esperion Therapeutics announces special shareholder meeting on merger agreement

Reuters
·
Jun 17

Esperion Therapeutics announces shareholder meeting on merger agreement

Reuters
·
Jun 10

Green steel, grey area: The definition vacuum fracturing a critical market

Fastmarkets
·
Jun 09

Esperion Therapeutics shareholders approve 7 million-share increase to 2022 equity plan

Reuters
·
Jun 02

Esperion presents new data from CLEAR Outcomes, CLEAR Phase 2 study

TIPRANKS
·
May 26

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

GlobeNewswire
·
May 26

Esperion grants 260,000 RSUs to 23 new employees under inducement plan

Reuters
·
May 15

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 15

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
May 15

Esperion reports Phase 2 pediatric study shows bempedoic acid lowers LDL-C in HeFH

Reuters
·
May 13

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

GlobeNewswire
·
May 13

Analysts’ Top Healthcare Picks: Passage Bio (PASG), Esperion (ESPR)

TIPRANKS
·
May 13

Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk

TIPRANKS
·
May 10

Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives

Simply Wall St.
·
May 10

EXE, IP, ESPR, CMPS, TNXP Trending With Analysts

TIPRANKS
·
May 09